New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy

Join us for a live interactive webinar to learn more about the use of PARP inhibitors in patients with ovarian cancer, evaluating available long-term data from clinical trials, identifying patients most likely to benefit from PARP inhibitor therapy as single agents or in combination, and managing adverse events. This webinar will offer attendees the opportunity to have their questions answered by an expert panel.

Please note: You must be registered to attend the 2021 International Gynecologic Cancer Society Annual Global Meeting to attend this symposium. To Register:


Welcome, Introduction, and Baseline Assessment

Advances in ovarian cancer: evolving landscape for PARP inhibitors

Biomarkers in ovarian cancer; BRCA and beyond?

Clinical application of PARP inhibitors

Summary, Final Thoughts, Posteducation Assessment, and Audience

Question and Answer Session


Date / Time
Event Details


Nicoletta Colombo, MD

Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Philipp Harter, MD, PhD

Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany

Alexandra Leary, MD, PhD

Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Goal Statement
The goal of this activity is to educate global gynecologic oncologists, medical oncologists, and other healthcare professionals about the recent developments in the use of PARP inhibitors in the treatment of ovarian cancer.

Target Audience
This educational program is intended for global gynecologic oncologists, medical oncologists, and other healthcare professionals who care for patients with ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate available long-term follow-up data from clinical trials investigating the use of PARP inhibitors in the management of ovarian cancer
  • Plan PARP inhibitor–based therapeutic strategies for patients with ovarian cancer based on available data, long-term clinical experience, expert recommendations, and patient preferences
  • Identify patients with ovarian cancer most likely to benefit from PARP inhibitor therapy as single agents or in combination
  • Compare and contrast the toxicities associated with PARP inhibitors commonly used in therapy for ovarian cancer, and understand the available supportive management strategies
  • Discuss with patients and colleagues ongoing clinical studies of PARP inhibitor–based treatment in ovarian cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.